Last updated: February 23, 2026
What is NDC 65219-0028?
NDC 65219-0028 is the National Drug Code for Fostemsavir, an antiretroviral drug approved for the treatment of HIV-1 infection. Approved by the FDA in July 2020, Fostemsavir (brand name Rukobia) is indicated for heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.
Market Overview
Market Size
The global HIV market was valued at approximately $20 billion in 2022, with the U.S. accounting for roughly 45%. The HIV treatment segment makes up 70-80% of this figure, with an increasing focus on multi-drug resistant (MDR) cases due to rising resistance to existing therapies.
Patient Demographics
- Estimated U.S. patients eligible for Fostemsavir: ~12,000.
- Global eligible patients: roughly 50,000, primarily in regions with higher MDR HIV prevalence.
- Untreated or extensively resistant cases constitute a small, high-margin market.
Competitive Landscape
Main competitors include integrase inhibitors and other entry inhibitors:
- Biktarvy (Gilead Sciences)
- Tivicay (Gilead Sciences)
- Darunavir (AbbVie)
- Cabotegravir (ViiV Healthcare)
Fostemsavir’s niche is heavily treatment-experienced patients with limited options, leading to high pricing power.
Adoption Trends
- Limited initial market share (estimated 5-8%) in 2022 due to recent approval.
- Growth driven by increased awareness and favorable guidelines for resistant cases.
- Surge in use expected as more data supports efficacy and safety.
Pricing Analysis
List Price
- The wholesale acquisition cost (WAC) for Fostemsavir was approximately $3,200 per month as of 2022, based on initial launches.
- Price variations exist across regions, with U.S. prices generally higher than international markets.
Reimbursement and Insurance Coverage
- Typically reimbursed through Medicaid, Medicare Part D, and commercial insurance.
- Co-pays vary, but high-cost drugs often face coverage restrictions, impacting patient access.
Cost Comparison
| Drug |
Monthly Cost |
Indication |
Resistance Profile |
| Fostemsavir (Rukobia) |
~$3,200 |
Heavily treatment-experienced HIV |
MDR HIV, limited options |
| Biktarvy |
~$2,000 |
First-line HIV |
Standard resistance profile |
| Darunavir |
~$2,200 |
Multidrug-resistant HIV |
Cross-resistance issues |
Price Trends & Projections
- Initial launch prices set at premium levels, reflecting the niche market.
- Expected decreases of 10-15% annually over 3-5 years due to increased competition, biosimilars, and market expansion.
- Usage is limited initially but projected to grow as prescribing guidelines evolve.
Market Penetration & Revenue Projections
Assuming a gradual market share increase:
- Year 1: 5% of the MDR HIV market (~600 patients), revenue approx. $23 million.
- Year 3: 15% market penetration (~1,800 patients), revenue approx. $70 million.
- Year 5: 25% market share (~3,000 patients), revenue nearing $115 million.
Regulatory & Policy Influences
- Price negotiations through U.S. Medicaid and Medicare could lower net prices.
- International pricing policies vary, affecting global revenue.
Key Price and Market Drivers
- Efficacy in resistant cases enhances value.
- Label expansion to broader HIV populations could boost demand.
- Competitive drugs entering the resistant HIV segment might pressure price points.
Risks & Constraints
- Emerging resistance could limit use.
- Payer pushback on cost may lead to formulary restrictions.
- Market uptake highly sensitive to clinical guidelines and real-world data.
Summary
Fostemsavir’s market remains niche but has high revenue potential within resistant HIV treatment. The initial price point of ~$3,200/month places it among premium antiretrovirals, with a downward trend expected over the next five years. Market growth hinges on increased recognition of resistant HIV, expanding indications, and competitive dynamics.
Key Takeaways
- NDC 65219-0028 (Fostemsavir) targets a limited but high-value segment of the HIV market.
- The initial list price is approximately $3,200 per month, with potential price reductions over time.
- Revenue projections suggest growth from under $25 million in Year 1 to over $100 million by Year 5.
- Market expansion depends on clinical adoption, guideline updates, and resistance patterns.
- Competition and payer negotiations could significantly influence pricing and market share.
FAQs
1. What is the primary patient population for Fostemsavir?
Patients with multidrug-resistant HIV who have limited treatment options.
2. How does the price of Fostemsavir compare to other HIV drugs?
It has a higher initial price (~$3,200/month) compared to standard first-line therapies, which typically cost around $2,000/month.
3. What factors could reduce the drug’s price over time?
Market competition, biosimilar entry, and payer negotiations are primary drivers.
4. How quickly is Fostemsavir likely to increase market share?
Gradual increase over 3-5 years, reaching approximately 25% of the MDR HIV niche by Year 5.
5. Are there international price differences?
Yes, prices are generally lower outside the U.S., reflecting regional pricing policies and market dynamics.
References
- FDA. (2020). Fostemsavir approval announcement. Retrieved from FDA.gov
- IQVIA. (2022). Global HIV market report.
- Medtrack. (2022). Data on drug pricing and formulary status.
- Gilead Sciences. (2021). Product monograph for Biktarvy.
- ViiV Healthcare. (2022). HIV resistance therapy pipeline update.
